ARCHIVES

FDA Approves Avastin For Recurrent NSCLC

This article is from The Cancer Letter archive.

Vol. 29 No. 10 | October 27, 2006

Download PDF Visit The Full Archive

Related Articles

Phase III Xilonix Study Halted Following Unscheduled Analysis

September 26, 2014

Society Support Program for Training Cytotechnologists

November 29, 1991

More Clinical Trials Money Top Priority, DeVita Says; Drug Discovery Groups RFA Gets 12 Applications

February 24, 1984

NCI Advisory Group Meetings for September

August 29, 1975

Hard imes For Cancer Control – Six Contracts Ended; Rochester’s Community Proposal Rejected

October 1, 1976

Congress Approves $4.19 Billion For NCI, $23.5 Billion For NIH, In FY2002 Appropriation.

January 4, 2002